Vitaspring Biomedical Co. Ltd. Stock Analysis VSBC
VitaSpring Biomedical Co. Ltd. engages in the research and development of stem cell applications in regenerative medicine and the establishment of advanced medical research centers and high standard cell production centers. The company is headquartered in Riverside, California and currently employs 0 full-time employees. The company went IPO on 2019-10-01. The firm invests in research and development of stem cell applications in regenerative medicine, establishes advanced medical research centers and cell production centers, and provides GTP standard stem cell preparations for the development of cellular drugs. The GTP Cell Center is the basis for its business, which is cross-domain in biotechnology medical treatment, medicine and medical materials, and focuses on the development of cell medical treatment. Its GTP standard stem cell production center is in Taipei, Taiwan for mass production of its mesenchymal stem cell (MSC), exesome, and cytopharmaceuticals. The company also cooperates with affiliated companies to support the mass production and commercialization of X.MSC-related medical projects.
Read More Vitaspring Biomedical Co. Ltd (VSBC) Chart
Key Statistics of Vitaspring Biomedical Co. Ltd (VSBC)
Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.
Today's Range
Today's Open
$0.01Volume
408.00P/E Ratio (TTM)
1.8252 Week Range
Market Cap
2.30MAvg. Volume
408.00Dividend Yield
-Financial Metrics & Statements of Vitaspring Biomedical Co. Ltd (VSBC)
FAQ's for Vitaspring Biomedical Co. Ltd (VSBC)
- According to Musaffa’s Shariah screening methodology, Vitaspring Biomedical Co. Ltd (VSBC) is currently classified as NOT COVERED as of May 2026. The classification is based on an evaluation of the company’s business activities and financial ratios to determine whether it meets Islamic investment guidelines.